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OBJECTIVE—To ascertain the importance and mechanisms
underlying the role of brain glucagon-like peptide (GLP)-1 in the
control of metabolic and cardiovascular function. GLP-1 is a gut
hormone secreted in response to oral glucose absorption that
regulates glucose metabolism and cardiovascular function.
GLP-1 is also produced in the brain, where its contribution to
central regulation of metabolic and cardiovascular homeostasis
remains incompletely understood.
RESEARCH DESIGN AND METHODS—Awake free-moving
mice were infused with the GLP-1 receptor agonist exendin-4
(Ex4) into the lateral ventricle of the brain in the basal state or
during hyperinsulinemic eu-/hyperglycemic clamps. Arterial fem-
oral blood ﬂow, whole-body insulin-stimulated glucose utiliza-
tion, and heart rates were continuously recorded.
RESULTS—A continuous 3-h brain infusion of Ex4 decreased
femoral arterial blood ﬂow and whole-body glucose utilization in
the awake free-moving mouse clamped in a hyperinsulinemic-
hyperglycemic condition, only demonstrating that this effect was
strictly glucose dependent. However, the heart rate remained
unchanged. The metabolic and vascular effects of Ex4 were
markedly attenuated by central infusion of the GLP-1 receptor
(GLP-1R) antagonist exendin-9 (Ex9) and totally abolished in
GLP-1 receptor knockout mice. A correlation was observed
between the metabolic rate and the vascular ﬂow in control and
Ex4-infused mice, which disappeared in Ex9 and GLP-1R knock-
out mice. Moreover, hypothalamic nitric oxide synthase activity
and the concentration of reactive oxygen species (ROS) were
also reduced in a GLP-1R–dependent manner, whereas the
glutathione antioxidant capacity was increased. Central GLP-1
activated vagus nerve activity, and complementation with ROS
donor dose-dependently reversed the effect of brain GLP-1
signaling on peripheral blood ﬂow.
CONCLUSIONS—Our data demonstrate that central GLP-1
signaling is an essential component of circuits integrating
cardiovascular and metabolic responses to hyperglycemia.
Diabetes 57:2577–2587, 2008
T
here is now compelling evidence supporting the
interplay between metabolic and vascular dis-
eases (1,2) in which neuronal circuits in the
central nervous system seem to play a critical
role in orchestrating the control of glucose homeostasis
(3). We recently demonstrated that the central infusion of
insulin decreased blood pressure and increased arterial
blood ﬂow and heart rate through a molecular mechanism
depending on the synthesis of nitric oxide in the hypothal-
amus (4). Importantly, the central regulation of nitric
oxide (NO) metabolism affected whole-body glucose utili-
zation (5). This mechanism was impaired during high-fat
diet–induced insulin resistance and diabetes and reverted
upon central NO supplementation (4). These ﬁndings raise
the possibility that signals from peripheral tissues, which
act on the brain to control glucose metabolism, could also
regulate vascular function.
Enteroendocrine cells have important roles in regulating
energy intake and glucose homeostasis through their
actions on peripheral target organs, including the endo-
crine pancreas. Enteroendocrine cells secrete multiple
hormones, including glucagon-like peptide (GLP)-1, which
controls pancreatic endocrine secretion (6). GLP-1 is also
a neuropeptide synthesized by neurons in the caudal
regions of the nucleus of the solitary tract (NTS) (7,8).
GLP-1 is released into the hypothalamus and controls food
intake, blood pressure, and heart rate (9,10). Whereas
most of the glucose-lowering actions of GLP-1 have been
attributed to the direct effect of the hormone on the
endocrine pancreas, i.e., to stimulation of insulin and
inhibition of glucagon secretion, we demonstrated the
importance of extra-pancreatic GLP-1 receptor–depen-
dent control of insulin secretion (11) and whole-body
glucose distribution (12). The infusion into the brain of the
GLP-1 receptor antagonist exendin-9 (Ex9) inhibited insu-
lin secretion induced by gut glucose (11). Conversely,
central administration of the GLP-1 receptor agonist ex-
endin-4 (Ex4) augmented intravenous glucose-stimulated
insulin secretion to a level similar to that obtained during
an intragastric glucose infusion (11). Our data suggested
that the absorptive state was associated with the stimula-
tion of the gut-to-brain axis leading to the activation of
brain GLP-1 signaling and, consequently, to hyperinsulin-
emia. During the absorptive state, blood ﬂow redistribu-
tion toward mesenteric organs is also observed, which has
been proposed to favor nutrient redistribution into the
liver (13). Importantly, stimulation of the central GLP-1
receptor increases blood pressure and heart rate and
activates autonomic regulatory neurons (8,14,15). How-
ever, recently it has been shown that GLP-1 reduced
islet blood ﬂow after glucose administration (16). There-
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DIABETES, VOL. 57, OCTOBER 2008 2577fore, the role of brain GLP-1 signaling also in the control
of cardiovascular homeostasis remains incompletely
understood.
We have now pursued the importance of GLP-1 action in
the central nervous system for control of cardiovascular
function using studies in conscious free-moving mice.
After central GLP-1 infusion, we simultaneously recorded
femoral arterial blood ﬂow, heart rate, and insulin and
glucose sensitivity during hyperinsulinemic-euglycemic or
hyperglycemic clamps. We now demonstrate that hypotha-
lamic reactive oxygen and nitrogen species are controlled
by brain GLP-1 and are essential for the coordinated
regulation of metabolic and cardiovascular function.
RESEARCH DESIGN AND METHODS
Animals. Experiments were carried out under protocols approved by the
Institutional Animal Care and Use Committee. Eleven-week-old male
C57BL/6J (Janvier, Larbresle, France) and GLP-1 receptor knockout mice
from our colony (in C57BL/6 background) were used, as previously described
(4). Throughout the study period, the mice were housed at 21–22°C with a
normal daily cycle and food and water ad libitum.
Surgical procedures. A catheter (Charles River Laboratories, L’Arbresles,
France) was inserted into the lateral cerebral ventricle and secured on the top
of the skull under anesthesia with isoﬂurane-oxygen (17). Ten days after the
intracerebroventricular surgery, an intravenous catheter was introduced into
the left femoral vein, sealed under the skin, and externalized at the back of the
neck (Fig. 1). The mice were allowed to recover for 3 days, before an
ultrasonic ﬂow probe (Transonic System, Emka Technologies, France) was
inserted surrounding the right femoral artery. The probe wire was inserted
through the skin at the back of the neck, where it was secured using surgical
thread. After surgery, the mice returned to their cages and allowed to recover
for at least 4 days before infusions (18). At the end of the recovery period,
mice that did not reach their presurgery weights were not used for subsequent
experiments (i.e., 15% of the animals).
Infusions. On the day of the study (Fig. 1), the ﬂow probe wire was
connected to a Transonic model T403 ﬂowmeter (Transonic System; Emka
Technologies, Paris, France) to record the blood ﬂow (ml/min) of the femoral
artery and the heart rate (beats/min). The basal femoral arterial blood ﬂow
and heart rate were recorded for 30 min in overnight fasted free-moving mice
before starting the infusions.
Glucose clamp. A hyperinsulinemic-euglycemic (5.5 mmol/l) or hyperglyce-
mic (20 mmol/l) clamp was performed to activate GLP-1–sensitive cells and to
assess whole-body glucose utilization (18) (Table 1). Brieﬂy, insulin was
infused through the intrafemoral catheter at a rate of 18 mU  kg
1  min
1 for
3 h. Glycemia was clamped at 5.5 or 20 mmol/l by adjusting an intrafemoral
glucose infusion. A control group was infused with NaCl 0.9% (saline) for 3 h
at a rate that was matched to the mean glucose infusion rate during the
hyperinsulinemic clamps. This procedure did not change the hematocrit value,
which remained close, ranging between 38.3 and 39.1% when considering all
groups.
To ensure the ﬁlling of the tubing connected to the brain, intracerebroven-
tricular infusions were started 30 min before the beginning of the clamp
procedure and continued throughout the whole study. Brieﬂy, a 5-l bolus (5
l) followed by a continuous (12 l/h) infusion was performed with the
cerebral vehicle (artiﬁcial cerebrospinal ﬂuid [aCSF], pH 7.35, Na
 144
mmol/l, Cl
 146 mmol/l, K
 3 mmol/l, Mg
2 1 mmol/l, Ca
2 1.5 mmol/l, PO
4
1.2 mmol/l, pH 7.35) or with the GLP-1 receptor agonist (Ex4) or antagonist
(exendin 9 [Ex9]), at a rate of 0.5 pmol  kg
1  min
1 for 3 h, as described
(11,12). This Exh infusion is expected to result in cerebral supraphysiological
concentrations of GLP-1. However, this exendin infusion rate is 10 times lower
than the one required to induce a physiological effect using a systemic infu-
sion (11,12).
Measurement of autonomic nervous system activity. To assess the vagus
nerve activity, a subset of mice bearing an intracerebroventricular catheter for
1 week was anesthetized with isoﬂurane maintained on a heating blanket at
37°C in a Faraday cage. The vagus nerve was isolated from the carotid at the
level of the trachea, and one monopolar platinum electrode (Diameter: 125
m, Phymep, Paris, France) was approximated to the vagal nerve. A second
electrode was implanted directly on the skin as a reference. Both electrodes
were connected to a BioAMp ampliﬁcator system (Ad Instrument; Phymep,
Paris, France). The signal was ﬁltered between 0.1 to 1,000 Hz (low and high
frequency). The output signal was then directed toward a data acquisition
system (PowerLab 8/30, Ad instrument). The neural activity was quantiﬁed by
counting the frequency of spikes that exceeded a voltage threshold level set
just above the electrical noise by using the Spike Histogram software
(computer program Chart 5, Ad instrument). Baseline unit activity was
recorded for 10 min before and during brain infusions. The neural activity was
continuously recorded and quantiﬁed for 10 min at different time periods
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FIG. 1. Surgical and experimental procedures. A: Seventeen days (J-17) before infusions and clamp studies, a catheter was indwelled into the
brain lateral ventricle. Seven days before the infusion (J-7), a catheter was indwelled into the left femoral vein, and the ﬂow probe was indwelled
4 days (J-4) before the infusions (J0). B: Thirty minutes before the infusions, Ex4, Ex9, or aCSF was infused into the lateral ventricle of the
mouse until completion of the 3-h clamp procedure. The clamp procedure was initiated by a concomitant infusion of glucose and insulin and was
compared with the saline intravenous infusions.
GLP-1 IN METABOLIC AND CARDIOVASCULAR FUNCTION
2578 DIABETES, VOL. 57, OCTOBER 2008during the brain infusions. At completion of the recording, 600 g acetylcho-
line chloride was injected intraperitoneally to demonstrate appropriate re-
sponsivity and recording of the vagus nerve activity.
Hydrogen peroxide infusions. To study the role of reactive oxygen species
(ROS) in the brain on arterial blood ﬂow, heart rate, and whole-body glucose
utilization, hydrogen peroxide (H2O2) was infused into the lateral ventricle of
the mice 120 min after the beginning of the hyperglycemic clamp. Hydrogen
peroxide was extemporaneously diluted in aCSF and infused at the rates of 2
or 20 nmol/min, as previously described (19). Brieﬂy, 2 lH 2O2 was followed
by a continuous infusion at a rate of 12 l/h. At the end of the infusions, the
mice were decapitated and the brain was removed from the skull within 15
s. The brain was put into a frozen brain frame and the hypothalamus was
dissected out and frozen at 80°C. To validate that the probe was correctly
recording the blood ﬂow, at the end of the insulin infusion, some mice were
given a ﬂash injection of a rapid NO donor (sodium nitroprusside (10 mg/kg,
25–40 l i.v.). Upon a correct implantation of the probe, the nitroprusside
injection induced at least a 100% increase in blood ﬂow and a rapid increase
in heart rate.
Blood sampling. At the end of the intracerebroventricular infusions, blood
was collected from the retro-orbital sinus into a tube, mixed with 1 g/l
aprotinin/0.1 mmol/l EDTA, and centrifuged at 8,000 rpm for 5 min at 4°C.
Plasma was stored at 80°C until assay. The insulin level was measured using
an ELISA kit (Mercodia, Sweden). Brieﬂy, 10 l plasma was incubated for 2 h
in the anti-insulin antibody–coated 96-well plate. Then, after washing the
secondary, antibody conjugated with peroxidase was added for 30 min. The
reaction was stopped by adding acid to give a colorimetric end point that is
read spectrophotometrically. The interassay variation coefﬁcient was 8%
and the intra-assay coefﬁcient was 4%.
Hypothalamic ROS and glutathione determinations. Tissue treatment for
ROS determination was accomplished according to the method of Szabados et
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FIG. 2. Hyperinsulinemia controls arterial blood ﬂow, heart, and
whole-body glucose utilization rates in wild-type mice. Percent changes
are shown from baseline of mean arterial femoral blood ﬂow (A) and
heart rates (B) during3ho fhyperinsulinemic-euglycemic conditions
where aCSF (f) or Ex4 () was simultaneously infused into the brain
of awake free-moving C57BL/6 J wild-type mice. In a subset of wild-
type mice, where aCSF was infused into the brain, intravenous saline
was simultaneously infused instead of glucose or insulin (control
group, F). Data are means  SE for six to seven mice per group and
signiﬁcantly different between the control group and the two other
groups (P < 0.05). In C, whole-body glucose utilization rate, glucose
infusion rate (GIR) (mg  kg
1  min
1), was calculated in steady-state
euglycemic-hyperinsulinemic conditions (5.5 mmol/l) in mice infused
with aCSF or Ex4 into the brain. Means  SE are shown for six to seven
mice per group.
TABLE 1
Summary of experimental conditions
Studies protocols n
1: Clamps
Euglycemic clamps
aCSF (icv) 7
Ex4 (icv) 6
Hyperglycemic clamps
aCSF (icv) 7
aCSF (icv) (GLP-1R KO) 6
Ex4 (icv) 7
Ex9 (icv) 5
Ex4  hydrogen peroxide (20 nmol/min) (icv) 5
2: Saline intravenous infusion
aCSF (icv) 6
3: Basal blood ﬂow and heart rate studies
aCSF (icv) 7
Ex4 (icv) 12
Ex9 (icv) 8
PBS (icv) 4
Hydrogen peroxide (2 nmol/min, icv) 4
Hydrogen peroxide (20 nmol/min, icv) 5
4: Vagal activity studies
aCSF (icv) 5
Ex4 (icv) 4
5: ROS studies
aCSF (icv, saline iv, WT) 5
aCSF (icv, clamp 5.5 mmol/l, WT) 15
aCSF (icv, clamp 20 mmol/l, WT) 10
Ex4 (icv, clamp 5.5 mmol/l, WT) 8
Ex4 (icv, clamp 20 mmol/l, WT) 14
aCSF (icv, clamp 5.5 mmol/l, GLP-1R KO) 5
aCSF (icv, clamp 20 mmol/l, GLP-1R KO) 5
6: NOS activity studies
aCSF (icv, clamp 20 mmol/l) 5
Ex4 (icv, clamp 20 mmol/l) 5
The number of mice studied (n) is indicated for each experimental
condition. aCSF, mice infused with artiﬁcial cerebrospinal ﬂuid into
the brain (intracerebroventricular icv). Some mice were clamped
with insulin in euglycemic or hyperglycemic conditions or under-
went a saline infusion equivalent to the corresponding insulin and
glucose infusion volumes and rates performed during the clamp
conditions. Some mice were studied in basal conditions (no insulin,
glucose, or saline infusion) only. Hydrogen peroxide was used at the
concentration of 2 or 20 nmol/min icv only, as speciﬁed. The vagal
activity was recorded in response to aCSF or Ex4 icv infusions in a
subset of mice. ROS production was assessed in all conditions in WT
or GLP-1 receptor knockout mice (GLP-1R KO) mice. The activity of
the NOS was studied in a subset of mice during hyperglycemic-
hyperinsulinemic clamp conditions in the presence or absence of
Ex4 icv.
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DIABETES, VOL. 57, OCTOBER 2008 2579al. (20). Brieﬂy, we used a rodent brain matrix (World Precision Instrument,
Sarasota, FL) to carefully slice out the hypothalamus and the surrounding
tissues. This frame allows an accurate and repeated sampling of a 1-mm-thick
brain slice. Then, a second frame is used to dissect out the hypothalamus
precisely and uniquely from the other part of the brain surrounding the
hypothalamus. Hypothalamic pieces were carefully homogenized using a
dounce and loaded with the dichlorodihydro-ﬂuorescein diacetate probe that
is oxidized to ﬂuorescent dichloroﬂuorescein by H2O2 and classically used to
monitor intracellular generation of ROS (CM-H2DCFDA, Molecular Probes). It
is noteworthy that this probe is very speciﬁc for H2O2 and that the background
level is very low. However, the origin of the ROS produced, i.e., mitochondrial
or cytoplasmic, cannot be detected. Hypothalamic homogenates were incu-
bated with 4 mol/l CM-H2DCFDA in a ﬁnal 0.5-ml volume for 30 min at 37°C.
After centrifugation, ROS measurements (on a 200-l supernatant) were
performed in a Fluorescent Plate Reader (Perkin Elmer). Intensity of ﬂuores-
cence was expressed as arbitrary units per milligram protein. Oxidized
glutathione/total glutathione ratio was assessed in hypothalamic homoge-
nates. They were immediately grounded in 1% EDTA/5% metaphosphoric acid
(1:5 vol/vol). After centrifugation, supernatants were used to detect total
reduced glutathione and its oxidized form (GSSG) by reverse-phase high-
performance liquid chromatography with electrochemical detection as de-
scribed (21).
Hypothalamic NO synthase activities. To assess hypothalamic NO syn-
thase (NOS) activities, the tissues were collected, weighted, and homogenized
in buffer (250 mmol/l Tris-HCl, 10 mmol/l EDTA and EGTA). The NOS assay kit
(Calbiochem, Darmstadt, Germany) is based on the biochemical conversion of
[
3H]-L-arginine to [
3H]-L-citrulline by NOS. The data are hence considered as an
index of NOS activity. NOS catalyzes the stoichiometric conversion of
L-arginine into L-citrulline in the presence of NADPH, oxygen, calmodulin, and
calcium. The tissues were incubated with radiolabeled [
3H]-L-arginine
(1 Ci/l) and passed through a column containing a resin that binds
L-arginine but not L-citrulline. The quantiﬁcation of [
3H]-L-citrulline radioac-
tivity is performed from the eluate. Results are expressed in counts per minute
by milligram of tissues.
Data analysis and statistics. Data are expressed as means  SE. Data were
analyzed using the GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego, CA). Statistical signiﬁcance was determined by applying,
respectively, a Student’s t test, a Mann-Whitney test, a Kruskal-Wallis followed
by a Dunn’s multiple comparison test, a Pearson test, or a two-way ANOVA
test for repeated measurements with ﬁxed factors of treatment/genotype,
time, and treatment/genotype 	 time followed by post hoc test (Bonferroni’s
multiple comparison test) when appropriate. The acceptable level of signiﬁ-
cance was deﬁned as P  0.05.
The Student’s t test was used for the glucose infusion rate and NOS
activities, since it is designed to compare two means together within a
binomial distribution. The Kruskal Wallis followed by the Dunn post hoc test
was used to compare more than two means together with single values
obtained during different experiments and was used for the comparison of
ROS activities. Eventually, we used the two-way ANOVA for repeated mea-
surements with ﬁxed factors followed by the Bonferroni post hoc test for all
time courses: heart rate, blood ﬂow, and vagal activities.
RESULTS
The activation of the central GLP-1 receptor regulates
femoral arterial blood ﬂow, heart rate, and whole-body
glucose utilization under hyperglycemic conditions. The
systemic infusion of insulin during a euglycemic-hyperinsu-
linemic clamp increased femoral blood ﬂow and heart rate
(Fig. 2Aand B). The simultaneous brain infusion of the GLP-1
receptor agonist Ex4 did not affect hemodynamic parameters
and whole-body glucose utilization (Fig. 2A–C) when the
mice were clamped under euglycemic conditions. Because
we previously demonstrated that brain GLP-1 signaling was
glucose-dependent (11), the blood glucose was raised to 20
mmol/l during the hyperinsulinemic clamp. Hyperglycemia
modestly diminished the relative increase in femoral arterial
blood ﬂow (compare Fig. 3A and 2A). Remarkably, coinfu-
sion of Ex4 into the brain under hyperglycemic conditions
abolished the increase in femoral artery blood ﬂow (Fig. 3A
and C). Simultaneously, hyperglycemia diminished the in-
crease in heart rate (Fig. 3B and D) observed under euglyce-
mic clamp conditions (compare Fig. 3B and 2B), but unlike
blood ﬂow, heart rate was not affected by Ex4. Concomi-
tantly, the whole-body glucose utilization rate was also
reduced by Ex4 (Fig. 3E). In contrast to the effects seen
under conditions of systemic hyperglycemia and hyper-
insulinemia, infusion of Ex4 into the lateral ventricle
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2580 DIABETES, VOL. 57, OCTOBER 2008had no effect on blood ﬂow and heart rate in the fasting
basal state (Fig. 3F and G).
To further examine the importance of endogenous GLP-1
receptor signaling for the control of femoral arterial blood
ﬂow and whole-body glucose utilization, we used 1) GLP-1
receptor knockout and 2) wild-type mice infused into the
brain with the GLP-1 receptor antagonist Ex9 under hyper-
insulinemic-hyperglycemic conditions. Remarkably, tran-
sient attenuation or genetic elimination of central GLP-1
receptor signaling markedly augmented femoral arterial
blood ﬂow (Fig. 4A). Similarly, heart rate was increased in
GLP-1 receptor knockout mice, and whole-body glucose
utilization rates were also increased by the disruption of
central GLP-1 receptor signaling (Fig. 4B and C).
Femoral arterial blood ﬂow correlates with whole-
body glucose utilization in the presence of an acti-
vated GLP-1 receptor. To determine whether the control
of whole-body glucose utilization by brain GLP-1 signaling
is intimately related to the rate of femoral arterial blood
ﬂow, we correlated both parameters for each mouse
independently, under different experimental conditions.
The data show that femoral arterial blood ﬂow and whole-
body glucose utilization rates were positively correlated
under hyperglycemic-hyperinsulinemic conditions (Fig.
5A) and the mean values of each group for both parame-
ters exhibited a highly signiﬁcant correlation (Fig. 5B). In
contrast, no correlation between femoral blood ﬂow and
glucose utilization was observed in mice with transient
central or complete genetic disruption of GLP-1 receptor
signaling (Fig. 5D) when compared with WT control mice
(Fig. 5C).
GLP-1 receptor activation decreases hypothalamic
nitric oxide synthase activity and reactive oxygen
species concentration. We previously showed that hy-
perinsulinemia increases femoral arterial blood ﬂow by a
mechanism requiring eNOS activation (4). Therefore, we
assessed the activity of nitric oxide synthases in the
hypothalamus of mice clamped in hyperglycemia and
infused with Ex4 into the brain. Central Ex4 signiﬁcantly
reduced total nitric oxide synthase activity (Fig. 6A).
Because ROS are also regulated by insulin and glucose in
the brain (22), we assessed the impact of glucose and Ex4
in vivo on ROS production. Hyperglycemia signiﬁcantly
reduced ROS production, which was even more markedly
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FIG. 3. Brain Ex4 controls arterial blood ﬂow,
heart rate, and whole-body glucose utilization in
normal mice during hyperglycemia. Percent
changes are shown from baseline of mean arterial
femoral blood ﬂow (A) and heart rates (B) during
3 h in hyperinsulinemic-hyperglycemic conditions
where aCSF (f) or Ex4 () was simultaneously
infused into the brain of C57BL/6 J wild-type
mice. Data are means  SE for seven mice per
group and are signiﬁcantly different from each
other for blood ﬂow data. In C and D, mean blood
ﬂow (ml/min) and heart rates (beats/min) are
shown in wild-type mice studied in the presence of
a brain infusion of Ex4 (Ex4; ) or aCSF (f).
Data are means  SE for 7 mice per group. In E,
whole-body glucose utilization rate, glucose infu-
sion rate (GIR) (mg  kg
1  min
1), was calculated
in steady-state hyperglycemic-hyperinsulinemic
conditions (20 mmol/l) in mice infused with aCSF
or Ex4 in the brain. Means  SE for seven mice
per group are shown. *P < 0.01 vs. intracerebro-
ventricular (icv) aCSF-infused mice. In F and G,
the percent changes are shown of blood ﬂow
change and heart rate during baseline, respec-
tively, in the presence of Ex4 (), Ex9 (E), or
aCSF (F), 7–11 mice per group. iv, intravenous.
C. CABOU AND ASSOCIATES
DIABETES, VOL. 57, OCTOBER 2008 2581suppressed by Ex4 in a glucose-dependent manner (Fig.
6B). Remarkably, the ability of glucose to diminish hypo-
thalamic ROS was completely abrogated in GLP-1 receptor
knockout mice (Fig. 6B). This reduced ROS concentration
was associated with an increased antioxidant capacity in
response to the Ex4 treatment and in hyperglycemia only,
since the oxidized glutathione–to–total glutathione ratio
was slightly reduced (Fig. 6C). However, we cannot rule
out that another antioxidant mechanism could also have
controlled the ROS production in response to brain GLP-1
signaling.
ROS in the central nervous system controls femoral
arterial blood ﬂow and whole-body glucose utiliza-
tion in a glucose-dependent manner. Because we
previously demonstrated that the pharmacological mod-
ulation of brain NO controlled femoral arterial blood ﬂow
and whole-body glucose utilization rates (4), we focused
here on the role of ROS. To determine whether changes in
ROS could link GLP-1 receptor activation to the control of
femoral arterial blood ﬂow and whole-body glucose utili-
zation rates, we performed a continuous infusion of oxy-
gen peroxide into the lateral ventricular cavity of control
mice under basal conditions. H2O2 induced a dose-depen-
dent increase in femoral arterial blood ﬂow (Fig. 7A). We
next determined whether H2O2 could reverse the effects of
Ex4 on blood ﬂow. The ROS donor was injected 120 min
after the beginning of the simultaneous hyperglycemic-
hyperinsulinemic clamp and Ex4 infusion (Fig. 7B). H2O2
dramatically and rapidly increased the arterial blood ﬂow
in the presence of Ex4 (Fig. 7B). Conversely, the heart rate
was reduced in the same experiments (Fig. 7C).
Vagus nerve activity is increased in response to brain
Ex4 administration. To determine whether the auto-
nomic nervous system is a candidate for transmission of
the brain GLP-1 signal to peripheral tissues, we recorded
vagus nerve activity during brain Ex4 infusion. Ex4 admin-
istration rapidly increased the ﬁring rate of the vagus
nerve within 5 min (Fig. 8B and C), which lasted for 55
min, i.e., until the end of the infusion (Fig. 8B and C).
DISCUSSION
The present data demonstrate that in the awake free-
moving mouse, brain GLP-1 receptor signaling simulta-
neously controls femoral arterial blood ﬂow, heart rate,
and glucose utilization. We further show that reactive
nitric oxide and oxygen species are regulated by brain
GLP-1 signaling and likely important for the coordinated
regulation of metabolic and cardiovascular function. The
brain to periphery signal was associated with an increased
vagus nerve activity. Notably, the action of GLP-1R signal-
ing for control of nitric oxide and ROS was strictly glucose
dependent.
We previously reported that brain GLP-1 induced insulin
resistance and increased insulin secretion to favor hepatic
glucose storage (11). We now extend these ﬁndings by
demonstrating that brain GLP-1 signaling reduces hind-
limb arterial blood ﬂow under conditions of hyperglyce-
mia. Hence, these new data strongly suggest that brain
GLP-1 signaling may modify the metabolic activity of
hindlimb muscles by a mechanism involving changes in
blood ﬂow. Consistent with this hypothesis, a strong
correlation was observed between glucose utilization and
blood ﬂow rates. Importantly, this correlation was no
longer present in experimental conditions where brain
GLP-1 signaling was abolished in GLP-1 receptor knockout
mice and, even more selectively, in mice infused with the
GLP-1 receptor antagonist Ex9 into the brain. It is note-
worthy that there is an important difference between the
blood ﬂow proﬁles obtained in the KO mice and those
obtained with the GLP-1 receptor antagonist Ex9. It is
suggested that either the GLP-1 receptor KO mice have
adapted to the genetic mutation or that the GLP-1 receptor
is also important to regulate blood ﬂow somewhere else in
the body. Recent evidence suggests that GLP-1 regulates
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FIG. 4. Brain GLP-1 receptor inactivation modulates arterial blood
ﬂow, heart rate, and whole-body glucose utilization in mice. Percent
changes from baseline of mean arterial femoral blood ﬂow (A) and
heart rates (B) during3hi nhyperinsulinemic-hyperglycemic condi-
tions, where aCSF was infused in the brain of wild-type (WT, f)o r
GLP-1 receptor knockout mice (KO, E), or in WT infused with Ex9 into
the brain (  ). Data are means  SE for 5–7 mice per group. Statistical
signiﬁcance was determined between mice infused with Ex9 or aCSF
and between GLP-1R KO mice and wild-type mice infused with aCSF (P
< 0.05 for the mean blood ﬂow data only). In C, whole-body glucose
utilization rate, glucose infusion rate (GIR) (mg  kg
1  min
1), was
calculated in steady-state hyperglycemic-hyperinsulinemic conditions
(20 mmol/l) in wild-type mice infused with aCSF or Ex9 in the brain and
in GLP-1 receptor knockout (KO) mice. *P < 0.05 vs. intracerebroven-
tricular (icv) aCSF-infused KO mice. iv, intravenous.
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dose-response manner (23), and GLP-1 is associated with
vasodilation induced by acetylcholine (24). In humans, the
systemic infusion of GLP-1 or its analogs does not induce
hypertension but, rather, has protective effects (25,26).
Therefore, the increased vascular resistance demonstrated
by the present data seems to be speciﬁc for brain GLP-1
signaling and not observed in response to a systemic
infusion. It is noteworthy that Ex4 is infused into the
brain and that the rate of infusion is so low that no
systemic effect could be detected (11). It is noteworthy
that our animal model was designed to study the
pharmacological effect of brain GLP-1 signaling on
vascular and metabolic functions. We performed hyper-
insulinemic-hyperglycemic clamps that do not corre-
spond to any physiological situation.
Therefore, we conclude that brain GLP-1 signaling contrib-
utes to the regulation of both metabolic and cardiovascular
functions. Importantly, we cannot directly demonstrate a
causal relationship between metabolic and vascular function
in response to brain GLP-1 signaling.
It has been previously shown that both intravenous and
intracerebroventricular administration of GLP-1 receptor
agonists increased blood pressure and heart rate (8). We
do not have direct evidence of changes in blood pressure
under our experimental conditions. However, because the
arterial femoral blood ﬂow was reduced in response to
brain Ex4 infusion, we could suggest that our data ﬁt
previous data from the literature. We here further demon-
strate that this increased blood pressure could be due to
an increased peripheral vascular resistance.
Moreover, GLP-1 receptors are also expressed in the
area postrema of the rat brain, which could interact with
circulating GLP-1 (27,28). In our experimental procedure,
hyperglycemia was induced by a systemic glucose infu-
sion; therefore, under these conditions, GLP-1 secretion
from the gut is not increased. Our data strongly support
the idea that central GLP-1 is a direct regulator of periph-
eral cardiovascular function. Furthermore, previous stud-
ies showed that the intracerebroventricular administration
of GLP-1R agonists increased arterial blood pressure and
heart rate, which was blocked by previous intracerebro-
ventricular administration of Ex9 (14). This is in agree-
ment with our data suggesting that this increased blood
pressure could be due to the reduced blood ﬂow that we
observed in the present study. Bilateral vagotomy blocked
the stimulating effect of intracerebroventricular GLP-1 on
arterial blood pressure and heart rate in rats (14). These
ﬁndings, taken together with our current data, suggest that
neural information emerging in the brain after GLP-1
receptor activation is transmitted to the periphery through
the vagus nerve. We previously reported that brain insulin
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FIG. 5. Correlations between femoral arterial blood ﬂow and whole-body glucose utilization rates under hyperglycemic conditions. The maximal
blood ﬂow rates (%) calculated during the hyperinsulinemic-hyperglycemic clamp were plotted in A against the glucose infusion rate (GIR, mg 
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1  min
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(f) or in GLP-1 receptor knockout mice (KO, Œ). In C, individual data are presented for mice with active brain GLP-1R signaling (wild-type aCSF
or Ex4-infused mice, n  14). In D, individual data are presented for mice where brain GLP-1 receptor signaling was blocked by Ex9 or in GLP-1R
knockout mice (KO) (n  11). The Pearson r value was calculated and a positive correlation was statistically signiﬁcant when P < 0.05.
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mechanism that does not require the cholinergic tone,
since the central insulin signal was not affected by atro-
pine (4). We suspected that noncholinergic ﬁbers would be
present in the vagus nerve. We here show that Ex4
activates the ﬁring activity of the vagus nerve and is
associated with vasoconstriction. Therefore, in the mouse,
the reduction of the arterial blood ﬂow might be associ-
ated with an increased activity of the vagus nerve. It is
noteworthy that we studied anesthetized mice in basal
conditions, where Ex4 alone was infused into the brain.
Therefore, more experiments should be done to validate
this conclusion in awake free-moving mice in response to
hyperglycemic-hyperinsulinemic clamps.
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0) and 5 (t  5) and 55 (t  55) min after the beginning of the intracerebroventricular (icv) aCSF (A) or Ex4 (B) infusions. At completion of
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in aCSF and Ex4-infused mice. *Signiﬁcantly different from aCSF-infused mice when P < 0.05.
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GLP-1 signaling was strictly glucose dependent. The glu-
cose dependency of GLP-1 signaling is a main general
feature. This characteristic minimizes the risk of hypo-
glycemia by blunting insulin secretion when glycemia
returns to the basal value. Here, we suggest that the
vascular effect of GLP-1 would also be blunted when the
blood glucose concentration reaches euglycemia. The
mechanisms responsible for the glucose dependency of
GLP-1 signaling into the brain are unknown but could be
related to those that we described into the portal vein
(12,29). For example, the glucose transporter GLUT2 is
probably a key of the brain glucose sensitivity (3,30).
Brain GLP-1 receptor signaling is activated in response to
oral glucose absorption (11), such as that in the fed condi-
tion. Glucose and insulin are two other important regulators
of brain signaling (31,32). We previously showed that brain
insulin increases femoral arterial blood ﬂow by a mechanism
depending on the production of NO by eNOS (4) and muscle
glucose utilization (17). We have now demonstrated that
brain GLP-1 signaling conversely decreased NOS activity and
prevented the vasodilatory effect of insulin in a glucose-
dependent manner. Hyperglycemia is absolutely required for
the control of GLP-1 action on glucose homeostasis (6), and
recent data showed that brain glucose sensing requires ROS
signaling. The transient increase from 5 to 20 mmol/l glucose
increased ROS concentration in hypothalamic slices ex vivo,
which is reversed by adding antioxidants (33). In our in vivo
experimental condition, i.e., 3 h of hyperglycemia and hyper-
insulinemia, the ROS concentration was reduced in the
hypothalamus. This was associated with an increased anti-
oxidative activity, since the oxidized glutathione/total gluta-
thione ratio was reduced. We cannot rule out that other ROS
scavenging mechanisms could have been activated in re-
sponse to Ex4. Our current data extend these ﬁndings by
demonstrating that 1) exogenous GLP-1R activation mark-
edly reduces glucose-dependent ROS generation and 2) basal
endogenous GLP-1R signaling is required for the transmis-
sion of the signal linking hyperglycemia to diminished ROS
generation. However, we cannot directly demonstrate that
the ROS concentration and GST activity changes were lo-
cated exclusively in GLP-1 receptor–expressing cells. Recent
data from our group and from the literature showed that
GLP-1 receptor–expressing cells are located at a high density
in the arcuate nucleus of the hypothalamus in the rats and
mice. Such cells are mainly associated with pro-opiomelano-
cortin (POMC)– and neuropeptide Y (NPY)–expressing neu-
rons (34,35). The interpretation would rather be that the
hypothalamic GLP-1–sensitive cells would transmit the
GLP-1 signal to multiple different cells in connection with the
former one. In addition, we used Ex4 instead of GLP-1 in our
infusion procedures to demonstrate the role of the GLP-1
receptor. We previously validated that brain Ex4 effects on
glucose metabolism and insulin sensitivity speciﬁcally de-
pended on brain GLP-1 receptors by studying GLP-1 receptor
knockout mice. Although we cannot exclude any unknown
Ex4-speciﬁc effect, our data strongly suggest that most if not
all the effects of Ex4 mimic native brain GLP-1 signaling.
In conclusion, the central nervous system is tightly
involved in the integrated control of blood glucose and
cardiovascular homeostasis. We have shown that, al-
though at a supraphysiological concentration, central
GLP-1 behaves as a molecular signal linking both meta-
bolic and cardiovascular functions. Recently, two new
therapeutic strategies based on GLP-1 have been approved
for the treatment of diabetes. One involves GLP-1 receptor
activation using GLP-1R agonists such as Ex4. The second
mechanism involves the prevention of endogenous GLP-1
degradation by the use of inhibitors of the GLP-1 degrad-
ing enzyme dipeptidyl peptidase-4. Although both strate-
gies lead to similar reduction of A1C in patients with type
2 diabetes, it seems reasonable to postulate that GLP-1R
agonists and dipeptidyl peptidase-4 inhibitors may pro-
duce different effects on brain mechanisms regulating
glucose homeostasis and cardiovascular function, an issue
that will be important to address in future studies.
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